Skip to main content
Premium Trial:

Request an Annual Quote

LumiraDx Gets CE Marks for SARS-CoV-2 Test, COVID-19-Flu Assay

NEW YORK — LumiraDx said on Wednesday that it has received CE marking for a molecular SARS-CoV-2 test and an assay that tests for both SARS-CoV-2 and influenza virus.

The Dual-Target SARS-CoV-2 STAR Complete test detects two gene markers to identify the presence of SARS-CoV-2, according to the company. The LumiraDx SARS-CoV-2 & Flu A/B RNA STAR Complete assay allows for the simultaneous detection and differentiation of influenza A, influenza B, and SARS-CoV-2.

Both tests use LumiraDx's qSTAR single-step nucleic acid extraction and amplification technology and run on open RT-PCR instruments. Results are provided within 20 minutes.

Last month, London-based LumiraDx reported an 18 percent increase in first quarter revenues on strong sales of its COVID-19 testing products.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.